DCLLSG

Recruiting Trials of the GCLLSG

First-Line Therapies for CLL

Currently no recruiting trials for First-Line Therapy.

Therapies for relapsed/refractory CLL

CLL2-BZAG
A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by obinutuzumab (GA101), zanubrutinib (BGB-3111) and venetoclax (ABT-199) in patients with relapsed/refractory CLL
» more

Therapies for Richter Transformation

CLL-RT1
A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK inhibitor, plus tislelizumab (BGB-A317), a PD1 inhibitor, for treatment of patients with Richter Transformation
» more

Transplantation Trials

Currently no recruiting transplantation trials